Last reviewed · How we verify

NCT06003309: FREED

Frequency and E-field Enhancement of ITBS for Depression (FREED)

Completed NA Last updated 13 February 2026
What this trial tests

NA trial testing Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS in Major Depressive Disorder in 75 participants. Completed in 30 December 2025.

Timeline
31 August 2023
Primary endpoint
30 December 2025
30 December 2025

Quick facts

Lead sponsorUniversity of California, San Diego
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment75
Start date31 August 2023
Primary completion30 December 2025
Estimated completion30 December 2025
Sites2 locations across United States, Australia

Drugs / interventions tested

Conditions studied

Sponsor

University of California, San Diego

Who can join

Adults 18 to 80, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators propose a randomized 3-arm double-blinded parallel experimental trial (20 sessions over 4 weeks) in 75 patients with TRD. The three arms include (1) the combination of a fully Individualized form of intermittent Theta Burst Stimulation (iTBS) (using BOTH the frequency and electric field (E-field) targeting approaches) (Ind-iTBS)), (2) iTBS individualized using E-field targeting only (targeted-iTBS) and (3) Standard iTBS treatment (i.e., typical iTBS localized to the dorsolateral prefrontal cortex (DLPFC) using the Beam F3 method). Electroencephalography (EEG) data will be collected at rest and during a working memory task, at baseline, and at the end of treatment along with clinical assessments of depression severity. The target engagement dependent variable of interest in these three arms will be fronto-parietal theta connectivity measured through resting-state EEG. The investigators hypothesize that stimulation with Ind-iTBS will lead to greater changes in fronto-parietal theta connectivity than that produced with targeted-TBS and standard iTBS. Aim: To evaluate the effects of two individualized forms of iTBS (i.e., using BOTH the frequency and E-field individualization; Ind-iTBS) compared to iTBS individualized for E-field targeting only (targeted-iTBS) and standard iTBS on fronto-parietal theta connectivity. Hypotheses: (1) Ind-iTBS will lead to greater changes in fronto-parietal theta connectivity compared to both targeted-iTBS and standard iTBS. (2) Ind-iTBS will also lead to a greater reduction in depressive symptoms (as defined by the mean reduction in Montgomery Åsberg Depression Rating Scale Scores (MADRS)) compared to both targeted-iTBS and standard iTBS.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Stochastic Approximator of Motor Threshold (SAMT) for Transcranial Magnetic Stimulation: Online Software and Its Performance in Clinical Studies.
    Wang B, Shah VU, Koponen LM, Neacsiu AD, et al · · 2026 · PMID 42226747 · DOI 10.1016/j.transm.2026.100312

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

Other University of California, San Diego trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06003309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing